harmacare
Commentary
Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
Melanie McPhail and Tania Bubela
The Authors Respond
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Eric Lun, Bob Nakagawa, Dean Regier, Shirin Rizzardo an...
Research Paper
Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective
Reed F. Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R. Houston, Aaron S. Kessel...
Research Paper
Exploring Privatization in Canadian Primary Care: An Environmental Scan of Primary Care Clinics Accepting Private Payment
Aidan Bodner, Sarah Spencer, M. Ruth Lavergne and Lindsay Hedden
Innovation in Health Services
Cost Impact of a Pharmacist-Driven Medication Reconciliation Program during Transitions to Long-Term Care and Retirement Homes
Denis O’Donnell, Carla Beaton, June Liang, Kisalaya Basu, Michael Hum, Amanda Propp, Liz Yanni, Y...
Discussion and Debate
Commentary: Expedited Regulatory Review of Low-Value Drugs
Jonathan J. Darrow and Reed F. Beall
Research Paper
Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle
Mina Tadrous, Tarry Ahuja, Basanti Ghosh and Rhonda Kropp
Research Paper
Ten Years of Inaction on Antimicrobial Resistance: An Environmental Scan of Policies in Canada from 2008 to 2018
Susan Rogers Van Katwyk, Jeremy M. Grimshaw and Steven J. Hoffman
CIHI Survey
Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Program
Kathy Lee, Trupti Jani, Roger Cheng and Jordan Hunt